Company Overview
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company based in the United States, with a primary focus on patients suffering from gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, particularly highly lethal esophageal adenocarcinoma. The company functions within the broader Healthcare sector and specifically within the Medical Devices industry, positioning itself to address diagnostic needs in a specialized therapeutic area. As of the latest available data, the company holds a market capitalization of $156.01M, generates annual revenue of $4.40M, and employs a workforce of 72 individuals. These financial and operational metrics indicate that Lucid Diagnostics is a small-cap entity with limited revenue relative to its market valuation, suggesting that the market is pricing in significant future growth potential or strategic value rather than current profitability. The disparity between its substantial market cap and modest revenue stream highlights the speculative nature of its stock price, which is often driven by the anticipated success of its diagnostic technologies rather than established earnings power.
Financial Health
Lucid Diagnostics reported a revenue of $4.40M over the trailing twelve months, yet this revenue generated a net income of $-65,844,000 and an EBITDA of $-47,119,000, revealing a cost structure where operating expenses vastly exceed income generation. The company's free cash flow stands at $-25,542,876, indicating that the business is currently burning cash, which limits its immediate financial flexibility and reliance on external capital sources for operations and development. The company's margin profile is severely negative across the board, with a gross margin of -58.1%, an operating margin of -971.0%, and a profit margin of 0.0%, collectively signaling that the company is not covering its direct or indirect costs with current sales. On the balance sheet, Lucid Diagnostics holds $48.38M in cash against $24.34M in debt, resulting in a debt-to-equity ratio of 94.19, which suggests a leveraged position despite the high absolute cash balance. The current ratio is reported at 1.90, indicating that the company possesses sufficient current assets to cover its short-term liabilities, providing a baseline of liquidity despite the overall negative financial performance. Return on Equity is listed at -331.2% and Return on Assets at -79.2%, metrics that reveal that management has not yet generated positive returns on the capital invested in the business or the assets it controls.
Valuation Assessment
The valuation metrics present a complex picture, with a trailing P/E Ratio (TTM) listed as N/A due to losses, while the forward P/E is calculated at -4.67, implying that the market expects earnings to remain negative or for the company to continue operating at a loss in the near term. The price-to-book ratio is recorded at -5.20, which indicates a negative book value and suggests that the market is valuing the company based on intangible factors or future prospects rather than the tangible assets currently recorded on its books. Alternative valuation metrics further highlight the disconnect between market price and operational reality, with a price-to-sales ratio of 35.46 and an EV/EBITDA of -3.95, suggesting that investors are paying a premium for revenue despite the lack of profitability. Regarding price momentum, the stock trades within a range defined by a 52-week high of $1.80 and a 52-week low of $0.95, meaning the current share price sits at a specific point within this historical volatility band. The stock exhibits a beta of 1.18, which indicates that the share price is more volatile than the broader market and is expected to amplify movements in the overall stock index.
Growth & Income
Lucid Diagnostics is showing modest expansion with a revenue growth rate of 3.3% year-over-year, while earnings growth is listed as N/A due to the absence of positive net income to grow from. The divergence between the positive revenue growth and the continued negative earnings suggests that top-line sales are increasing, but the underlying cost structure has not yet improved enough to generate profit, implying that the company is in a heavy investment or expansion phase. As a non-dividend payer, the company offers a dividend yield of N/A and maintains a payout ratio of 0.0%, indicating that the firm does not distribute cash to shareholders but instead retains all earnings to fund operations and growth initiatives. The overall growth and income profile of Lucid Diagnostics is characterized by low single-digit revenue expansion combined with significant cash burn, reflecting a high-risk, high-potential strategy typical of early-stage commercial diagnostics firms that have not yet achieved commercial viability.